Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAL-101 in Healthy Adult and Elderly Participants
NCT07780604Phase 1Completed
- Sponsor
- Galimedix Therapeutics
- Start
- Nov 2024
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gal-101 (20 arms), sponsored by Galimedix Therapeutics. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at 28 days. Started Nov 2024; status: completed.
02
Drugs
gal-101
Beyond the preview
Go deeper on NCT07780604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07780604.